SEC Form 4 · accession 0001077183-19-000033
NEOGENOMICS INC · NEO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sharon Virag
Officer — Chief Financial Officer
Period of report
Mar 1, 2019
Accepted (ET)
Mar 5, 2019 · 5:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001077183
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 1, 2019 | A | 10,944 | $0.00 | A | 10,944 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $19.60 | Mar 1, 2019 | A | 66,897 | A | Mar 1, 2020 | Mar 1, 2024 | Common Stock | 66,897 | 66,897 | D |
| Stock Option (Right to Buy)F2 | $8.22 | holding | — | — | — | Mar 27, 2019 | Mar 27, 2023 | Common Stock | 192,500 | 192,500 | D |
Explanation of responses
- F1On March 1, 2019, Ms. Virag was granted an option to purchase shares of NeoGenomics, Inc. common stock. The option vests ratably over the first four anniversary dates of the grant date.
- F2On March 27, 2018, Ms. Virag was granted an option to purchase shares of NeoGenomics, Inc. common stock. The option vests ratably over the first three anniversary dates of the grant date.